From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: GSK

Search articles by EPIC code

Why FTSE 100 stocks such as GSK and Vodafone are always worth thinking about (but only one of them is a buy today)

Many, many years ago, I remember somebody saying to me that investing in FTSE 100 stocks was pointless as “everything is priced in very efficiently”. What utter rubbish (as I told them at the time). Whilst the world of large cap stocks is covered by more analysts and mentioned more frequently by the press and financial TV, there are still plenty of opportunities to materially beat the index. And that is why today’s updates from both Vodafone (VOD) and (the previously named GlaxoSmithKline) GSK plc (GSK) are worth (at least) thinking about.
Page 1 of 7 (64 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments